Fungi: yeasts

Other Candida species

Candida glabrata (Nakaseomyces glabratus); Candida krusei (Pichia kudriavzevii); Candida parapsilosis; Candida tropicalis; Candida lusitaniae (Clavispora lusitaniae)

General medical information for education only, not medical advice. Treatment considerations summarize published guidance at drug-class level; therapy is chosen by the treating clinician using susceptibility results, local resistance patterns and current guidelines.

Overview

Non-albicans Candida species, increasingly common in vaginal, urinary and invasive infection, with species-specific antifungal patterns.

Infections

Bloodstream, urinary, vaginal and oral infection. C. glabrata and C. tropicalis are common causes of bloodstream infection; C. parapsilosis is linked to intravenous catheters and spread on the hands of healthcare workers; C. krusei is intrinsically resistant to fluconazole.

Signs and symptoms

Bloodstream infection: fever and chills that do not improve with antibiotics, usually in patients with central lines, recent surgery or an intensive-care stay. Urinary infection, mainly in catheterized patients; Candida in urine is often colonization without symptoms. Vaginal infection, notably with C. glabrata: itching, burning and discharge that can recur and respond poorly to standard treatment. Oral thrush: white patches and soreness.

Antibiotic and antimicrobial resistance

C. glabrata: reduced fluconazole susceptibility. C. krusei: intrinsically fluconazole-resistant. C. lusitaniae: may be resistant to amphotericin B. C. parapsilosis: higher echinocandin MICs.

Treatment considerations

Species identification guides therapy, with susceptibility testing for invasive infection.

Chromogenic agar plate with four Candida species in different colors, labelled
N. glabratus (C. glabrata), P. kudriavzevii (C. krusei), C. tropicalis and C. albicans on chromogenic agar. CC0. Image source
Yeast: budding cells and pseudohyphae, schematic
Yeast: budding cells and pseudohyphae. Schematic, not to scale; InnovexLab.

Sources

  1. CDC. Candidiasis.
  2. IDSA. Candidiasis guideline.
  3. CDC. Vulvovaginal candidiasis (STI Treatment Guidelines).

Sources accessed November 2026. Links open external sites that InnovexLab does not control.

Medical disclaimer

This page is general educational information summarized from published public-health and professional-society guidance. It is not medical advice, a diagnosis or a treatment recommendation, and reading it does not create a clinician–patient relationship with InnovexLab. Decisions about testing, diagnosis and treatment belong to the treating clinician, using the patient’s history and examination, laboratory and susceptibility results, local resistance patterns and current guidelines. Guidance changes over time; consult the original sources for the latest version. InnovexLab provides this information as is and does not warrant that it is complete or current.

Patients with questions about their health should contact their own healthcare provider. In an emergency, call 911.

Sources, image credits and editorial policy

Discuss a testing program with InnovexLab

Review the panel that fits your patients, its specimen requirements, and how results and billing work.